armodafinil NUVIGIL

Class: Wakefulness-promoting Agent
FDA Indications: Shift Work Sleep Disorder (SWSD), Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
Off-Label Use: Jet Lag, Treatment Resistant Depression, ADHD, Cocaine Addiction, Sleepiness Associated With Opioid Analgesia
FDA Schedule IV
Forms: 50, 150, 200, 250mg tablet
Dose Range: 150-250 mg/day
Starting: 150-250 mg qam
Stopping: Tapering unnecessary, though some patients may have sleepiness on discontinuation

NAMI drug fact sheet

Contraindications: Not recommended for use in patients with a h/o LVH, ischemic ECG Δ's, chest pain, arrhythmias or recent MI
Serious Side Effects:
Side Effects: headache (14-23%), anxiety, insomnia, xerostomia, nausea, palpitations, hypertension, rhinitis/rhinorrhea, diarrhea
1° MOA: Exact mechanism of action is unknown, but it is believed that the increase in synaptic dopamine following blockade of DAT leads to increased tonic firing and downstream effects on neurotransmitters including those involved in wakefulness, such as histamine and orexin/ hypocretin
Target: DAT, D2 partial agonist
t½: 15° TMAX:
Substrate of: 3A4
Inhibits: 2C19; Induces: 3A4
Active Metabolites:
  • - active R-enantiomer of modafinil
  • - the R and S enantiomers elicit similar effects, but the R enantiomer is more potent and delivers a longer effect
  • - novel mechanism of action and therapeutic uses with less abuse potential, but is often classified as a stimulant
  • - α1 antagonists (e.g., prazosin) may block its therapeutic actions
  • - may be useful in treating fatigue in patients with depression, multiple sclerosis, myotonic dystrophy and HIV/AIDS
  • - subjective sensation is generally normal wakefulness, not stimulation, but can occasionally include jitteriness
  • - may induce its own metabolism at high doses via 3A4 induction
Special Populations

Category Undefined.—Animal data suggest moderate risk, but limited human pregnancy experience prevents a full assessment of risk. Avoiding modafinil during pregnancy is the best course, but inadvertent exposure does not appear to represent a major risk of embryo-fetal harm

No reports describing the use of modafinil during human lactation have been located

Clearance of modafinil may be reduced in the elderly

There is inadequate information to determine safety and efficacy of dosing in patients with severe renal impairment

Dose should be reduced in patients with severe hepatic impairment


Developed & Designed by Kevin M. Nasky, D.O. • Built with Bootstrap, PHP & MySQL • Hosted by SiteGround
Last updated February 29 2024 20:54:18. Disclaimer: This website does not provide medical advice, nor is it a substitute for clinical judgment.